...as we try to improve the BCG vaccine, it is important that its beneficial ability to induce non-specific protection against irrelevant infections in newborn babies, through the phenomenon known as innate immune memory or trained immunity,10 is not lost. ...for now, we have to wait to see whether VPM1002 can induce comparable or better protection than existing BCG vaccines. Flickr - NIAID HMD was previously funded by the TBVAC2020 Consortium, which was funded by the EU Horizon 2020 programme, the Bill & Melinda Gates funded GC6–74 and GC6–2013 consortia, the EU FP7 funded Concurrent Tuberculosis and Diabetes Mellitus Consortium consortium, and the European and Developing Countries Clinical Trials Partnership funded AE-TBC and ScreenTB consortia, and is a current member of the EDCTP funded TriageTB consortium, which include several of the authors of the VPM1002 study but has had no role in the development of this vaccine.